OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas

January 24th 2024

Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.

Dr McAndrew on the Evolving Treatment Armamentarium for HER2+ Breast Cancer

January 24th 2024

Nicholas P. McAndrew, MD, MSCE, discusses the evolution of the treatment armamentarium for HER2-positive breast cancer, including the HER2CLIMB-02 trial.

Dr Siegel on the Importance of Real-World Data in Patients With Multiple Myeloma

January 24th 2024

David Samuel Dicapua Siegel, MD, emphasizes the importance of real-world evidence when treating patients with relapsed/refractory multiple myeloma.

Dr Miller on Updates With ADCs and Emerging Targets in Ovarian Cancer

January 24th 2024

Eirwen M. Miller, MD, discusses updates on antibody-drug conjugates and emerging targets in ovarian cancer.

Dr McAndrew on the Impact of the KATHERINE Trial in HER2+ Breast Cancer

January 23rd 2024

Nicholas P. McAndrew, MD, MSCE, discusses the impact of the phase 3 KATHERINE trial in patients with HER2-positive breast cancer.

Dr Dima on the Implications of a Real-World Analysis of Teclistamab in Multiple Myeloma

January 23rd 2024

Danai Dima, MD, discusses the implications of real-world data derived from the MajesTEC-1 trial in pretreated patients with multiple myeloma.

Dr Miller on the Impact of Mirvetuximab Soravtansine on Clinical Practice in Ovarian Cancer

January 23rd 2024

Eirwen M. Miller, MD, discusses how mirvetuximab soravtansine-gynx in ovarian cancer has bolstered the development of novel ADCs in ovarian cancer.

Dr Advani on the Role of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer

January 23rd 2024

Pooja Advani, MBBS, MD, discusses the potential utilization of capivasertib plus fulvestrant in hormone receptor–positive, HER2-negative breast cancers with PIK3/AKT/PTEN pathway alterations.

Dr Patel-Donnelly on the Management of High-Risk Hematologic Malignancies in the Community

January 22nd 2024

Dipti Patel-Donnelly, MD, discusses the management of high-risk hematologic malignancies in community practice.

Dr Melstrom on Challenges Implementing Widespread Molecular Testing in GI Cancer

January 22nd 2024

Laleh Melstrom, MD, MS, discusses using molecular testing to guide treatment selection for patient with gastrointestinal cancers.

Dr Barzi on the Real-World Use of Triplet Chemotherapies in mCRC

January 22nd 2024

Afsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.

Dr Kim on the Rationale For Investigating the Use of Regorafenib in mCRC

January 22nd 2024

Richard Kim, MD, discusses data from a real-world investigation of long-term responses with regorafenib in patients with metastatic colorectal cancer.

Dr Li on the Use of ADG126 With Pembrolizumab in MSS CRC

January 20th 2024

Daneng Li, MD, discusses a study utilizing of ADG126 in combination with pembrolizumab for patients with microsatellite stable colorectal cancer.

Dr Ludmir on the Rationale For the EXTEND Trial in PDAC

January 20th 2024

Ethan B. Ludmir, MD, shares the rationale for and the outcomes derived from the EXTEND trial in oligometastatic pancreatic ductal adenocarcinoma.

Dr Kasi on the Rationale for Analyzing ctDNA to Inform Chemotherapy Decisions in CRC

January 20th 2024

Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.

Dr Shitara on the 4-Year Outcomes of the CheckMate 649 Trial in GEJ Adenocarcinoma

January 20th 2024

Kohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.

Dr McCloskey on Flow Cytometry and Machine Learning in Hematologic Malignancy Diagnosis

January 20th 2024

James K. McCloskey, MD, discusses the potential for machine learning to replace flow cytometry analyses in patients with hematologic neoplasms.

Dr Vincelette on MYC Expression in Myelofibrosis

January 20th 2024

Nicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms.

Dr Lencioni on the Results of the EMERALD-1 Trial in Unresectable HCC

January 19th 2024

Riccardo Lencioni, MD, FSIR, EB, discusses the EMERALD-1 trial of TACE/durvalumab/bevacizumab in patients with unresectable hepatocellular carcinoma.

Dr Meisel on the Impact of Endocrine Therapy–Related Toxicities on QOL in ER+/HER2– Breast Cancer

January 19th 2024

Jane L. Meisel, MD, discusses the impact of toxicities associated with endocrine therapy on quality of life as reported by patients with metastatic breast cancer.